Clinical Trials · NCT05999968
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
- Phase
- Phase 1
- Recruitment status
- Terminated
- Sponsor
- Eli Lilly and Company
- Enrollment
- 10
- Start date
- Jan 2024
- Locations
- 13 sites, 3 countries
- Primary endpoint
- Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration